View Archive »
About The Cover
Corelation between EGFR endocytosis and gefitinib response in lung cancer cells with wtEGFR. See Jo et al.
|
|
Table of Contents
Editorial Materials
|
| Dopamine signaling: target in glioblastoma |
|
https://doi.org/10.18632/oncotarget.1835
|
| 1116-1117 |
Reviews
|
| AIDinduced remodeling of immunoglobulin genes and B cell fate |
|
https://doi.org/10.18632/oncotarget.1546
|
| 1118-1131 |
|
| Heat shock proteins in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.1584
|
| 1132-1148 |
Research Perspectives
|
| Dissecting the p53Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity |
|
https://doi.org/10.18632/oncotarget.1797
|
| 1149-1156 |
|
| Latest progress in tyrosine kinase inhibitors |
|
https://doi.org/10.18632/oncotarget.1836
|
| 1157-1161 |
Priority Research Papers
|
| Inhibition of the vacuolar ATPase induces Bnip3dependent death of cancer cells and a reduction in tumor burden and metastasis |
|
https://doi.org/10.18632/oncotarget.1699
|
| 1162-1173 |
|
| microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers |
|
https://doi.org/10.18632/oncotarget.1682
|
| 1174-1184 |
|
| Contact inhibition modulates intracellular levels of miR223 in a p27kip1dependent manner |
|
https://doi.org/10.18632/oncotarget.1803
|
| 1185-1197 |
|
| Identification of heat shock protein 32 Hsp32 as a novel target in acute lymphoblastic leukemia |
|
https://doi.org/10.18632/oncotarget.1805
|
| 1198-1211 |
|
| SLC25A1 or CIC is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker |
|
https://doi.org/10.18632/oncotarget.1831
|
| 1212-1225 |
|
| KIAA1114 a fulllength protein encoded by the trophinin gene is a novel surface marker for isolating tumorinitiating cells of multiple hepatocellular carcinoma subtypes |
|
https://doi.org/10.18632/oncotarget.1677
|
| 1226-1240 |
Research Papers
|
| COX2 overexpression increases malignant potential of human glioma cells through Id1 |
|
https://doi.org/10.18632/oncotarget.1370
|
| 1241-1252 |
|
| Interaction between the ADAMTS12 metalloprotease and fibulin2 induces tumorsuppressive effects in breast cancer cells |
|
https://doi.org/10.18632/oncotarget.1690
|
| 1253-1264 |
|
| EGFR endocytosis is a novel therapeutic target in lung cancer with wildtype EGFR |
|
https://doi.org/10.18632/oncotarget.1711
|
| 1265-1278 |
|
| p63 transcriptionally regulates the expression of matrix metallopeptidase 13 |
|
https://doi.org/10.18632/oncotarget.1778
|
| 1279-1289 |
|
| Arsenicinduced sublethal stress reprograms human bronchial epithelial cells to CD61¯ cancer stem cells |
|
https://doi.org/10.18632/oncotarget.1789
|
| 1290-1303 |
|
| Retaining MKP1 expression and attenuating JNKmediated apoptosis by RIP1 for cisplatin resistance through miR940 inhibition |
|
https://doi.org/10.18632/oncotarget.1798
|
| 1304-1314 |
|
| Epigenetic repression of phosphatidylethanolamine Nmethyltransferase PEMT in BRCA1mutated breast cancer |
|
https://doi.org/10.18632/oncotarget.1800
|
| 1315-1325 |
|
| Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensedreplication origins to fire at a normal rate |
|
https://doi.org/10.18632/oncotarget.1796
|
| 1326-1337 |
|
| MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme |
|
https://doi.org/10.18632/oncotarget.1793
|
| 1338-1351 |
|
| Targeted inhibition of cellsurface serine protease Hepsin blocks prostate cancer bone metastasis |
|
https://doi.org/10.18632/oncotarget.1817
|
| 1352-1362 |
|
| Targeting Aerobic Glycolysis and HIF1α Expression Enhance Imiquimodinduced Apoptosis in Cancer Cells |
|
https://doi.org/10.18632/oncotarget.1734
|
| 1363-1381 |
|
| Endothelial integrin α3β1 stabilizes carbohydratemediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane |
|
https://doi.org/10.18632/oncotarget.1837
|
| 1382-1389 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
